Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Cassava Sciences Inc. (“Cassava”) (NASDAQ: SAVA) securities between October 13, 2023 and March 25, 2025, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Cassava’s drug, simufilam, was not capable of abating the progression of Alzheimer’s Disease, even in mild to moderate cases; and (2) as a result, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On August 25, 2025, Plaintiffs filed an Amended Complaint . This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.